Imara Inc

NASDAQ:IMRA   3:59:50 PM EDT
2.88
-0.05 (-1.71%)
Products, Regulatory

Imara Announces Primary Endpoint Change In Tovinontrine Clinical Trial

Published: 11/22/2021 12:18 GMT
Imara Inc (IMRA) - Imara Announces Primary Endpoint Change in Ardent Phase 2b Clinical Trial of Tovinontrine (imr-687) in Sickle Cell Disease.
Imara Inc - Ardent Trial Remains on Track for Interim Analysis of Voc Rates in Q1 of 2022.
Imara Inc - Primary Endpoint to Be Changed to Annualized Rate of Vocs Following Written U.S. Food and Drug Administration Recommendation.